Inactive Instrument

Press Releases Silence Therapeutics plc London S.E.

Equities

GB0008433350

End-of-day quote London S.E. Other stock markets
- ^GBX	-

Apr. 19	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	MT
Apr. 16	European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Silence Therapeutics : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION - Form 6-K	Apr. 15	PU
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)	Apr. 08	BU
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights	Mar. 13	BU
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)	Mar. 13	BU
Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024	Feb. 28	BU
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial	Feb. 26	AQ
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial	Feb. 23	BU
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement	Feb. 05	BU
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	Jan. 31	BU
Gubra concludes the research agreement with UK Biotech	Jan. 26	AQ
Silence Therapeutics : Curtis Rambaran, MD, promoted to Chief Medical Officer Marie Wikström Lindholm, PhD, promoted to Chief Scientific Officer - Form 6-K	Dec. 01	PU
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments	Dec. 01	BU
Moa Technology hires for further growth with expansion of its leadership team – announcing appointment of CFO and US-based CBO to support advancement of next-generation herbicides	Nov. 20	AQ
Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results	Nov. 14	BU
Silence Therapeutics to Present at Jefferies London Healthcare Conference	Nov. 08	BU
Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease	Nov. 01	BU
Silence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference	23-09-26	BU
Silence Therapeutics to Participate in September Investor Conferences	23-09-06	BU
Silence Therapeutics Reports Second Quarter 2023 Results	23-08-16	BU
Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration	23-07-11	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Silence Therapeutics plc London S.E.

Equities

GB0008433350

Press Releases

Filters